Study Alleviates Concerns Over Early Pregnancy Use of GLP-1 Drugs

A new analysis indicates that the use of GLP-1 drugs, including Ozempic and Mounjaro, early in pregnancy may not significantly increase risks of non-live birth, adverse birth weight, or congenital malformations. However, while the data offers reassurance, current guidelines still recommend discontinuation before pregnancy.

In a significant finding, recent research suggests that using GLP-1 drugs, such as Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide, early in pregnancy is not cause for immediate concern.

Analyzed by Harvard T.H. Chan School of Public Health, the study observes that risks for adverse pregnancy outcomes do not significantly rise with the continuation of GLP-1 drugs into the first trimester compared to their non-continuation.

Nevertheless, health experts maintain that guidelines advising against GLP-1 use during pregnancy remain unchanged, but reassure women who inadvertently used these drugs that there is no substantial danger.